Clinical Trials Logo

Recurrent Cancer clinical trials

View clinical trials related to Recurrent Cancer.

Filter by:

NCT ID: NCT06372574 Recruiting - Solid Tumor, Adult Clinical Trials

A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors

Start date: July 1, 2024
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety, tolerability, and pharmacokinetics of RO7617991, and will make a preliminary assessment of the anti-tumor activity of RO7617991 in human leukocyte antigen (HLA)-A*02 eligible patients with locally advanced or metastatic melanoma-associated antigen A4 (MAGE-A4)-positive solid tumors.

NCT ID: NCT06208657 Not yet recruiting - Childhood Cancer Clinical Trials

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

Start date: March 2024
Phase: Phase 1/Phase 2
Study type: Interventional

A companion platform trial to test novel targeted agents based on the patient's tumor profile.

NCT ID: NCT06103617 Recruiting - Clinical trials for Head and Neck Cancer

Safety and Superiority of Penicillamine in Radiosensitization of Recurrent Head and Neck Cancer

Start date: November 15, 2023
Phase: Phase 2
Study type: Interventional

Our preclinical study confirmed that copper accumulation can lead to radioresistance in vitro and in vivo, and reducing the concentration of copper with copper chelator help to overcome radioresistance. Therefore, the investigators plan to carry out a prospective interventional phase II clinical trial to explore the safety and efficacy of penicillamine (a common copper chelator) as a radiosensitizer in the treatment of recurrent head and neck cancer.

NCT ID: NCT05990920 Active, not recruiting - Solid Tumor Clinical Trials

Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy

Start date: August 23, 2023
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to test SNK02 in participants with pathologically confirmed cancer that is refractory to conventional therapy. The main questions it aims to answer are: - Is SNK02 safety and tolerable when administered weekly as an intravenous infusion - What is the maximum dose that is tolerated of SNK02 Participants will be administered SNK02 weekly for 8 weeks and undergo medical evaluation to provide initial clinical safety data for the treatment of cancer with allogeneic NK cells as a monotherapy treatment.

NCT ID: NCT05958121 Recruiting - Cancer Clinical Trials

IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors

Start date: August 9, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA402 in patients with recurrent and/or refractory solid tumors. Primary objectives: - To determine the maximum tolerated dose and/or recommended dose for extension for IMA402 (Phase I) - To characterize the safety and tolerability of IMA402 (Phase I/II) - To evaluate anti-tumor activity of IMA402 (Phase II) Secondary objectives: - To evaluate the initial anti-tumor activity of IMA402 (Phase I) - To evaluate anti-tumor activity of IMA402 (Phase II) - To describe the PK of IMA402 (Phase I/II)

NCT ID: NCT05855811 Recruiting - Recurrent Cancer Clinical Trials

PREventing Second Cancers With DOSTARlimab

PREDOSTAR
Start date: July 26, 2023
Phase: Phase 2
Study type: Interventional

PredoSTAR is a multicenter, randomized, open-label phase II study proposed to patients at high risk of SPC and in whom the treatment of the FPC does not include immunotherapy. Dostarlimab treatment will be started within 6 months after the completion of treatment for localized FPC (i.e. after the end of last CT, RT cure or surgery with a wash-out period of 4 weeks before to start Dostarlimab). Eligible patients will be randomized (1:1) to receive: - Arm Dostarlimab : 4 intravenous (IV) injections of dostarlimab, Q3W or - Arm No treatment

NCT ID: NCT05626829 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma

Start date: July 20, 2022
Phase: Phase 2
Study type: Interventional

Nasopharyngeal carcinoma is one of the high incidence head and neck cancer in Southeast Asia. Radiotherapy is the main treatment for nasopharyngeal carcinoma, and its response rate can reach 80~90%. However, for radiotherapy resistant patients with metastasis and recurrence, the survival prognosis decreased significantly, and the 5-year overall survival rate was only 20% - 40%. Tranilast is an anti-allergic drug, which is clinically used to treat bronchial asthma and can inhibit fibroblasts α- SMA and type I collagen expression. Through experiments in vivo and in vitro, the investigators' research group has proved that Tranilast can inhibit the activity of tumor related fibroblasts, reduce the radiotherapy resistance of nasopharyngeal carcinoma, and has the radiosensitizing effect of nasopharyngeal carcinoma. This result has been published in J exp Clin cancer res (if=11.16). The investigators plan to carry out the clinical transformation of basic research, carry out a prospective intervention phase II clinical trial, compare the objective remission rate of patients with recurrent nasopharyngeal carcinoma treated with previous radiotherapy, and explore the safety and effectiveness of using Tranilast as a radiotherapy sensitizer for radiotherapy to resist the treatment of nasopharyngeal carcinoma.

NCT ID: NCT05415475 Recruiting - Colorectal Cancer Clinical Trials

Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors

Start date: September 10, 2021
Phase: Phase 1
Study type: Interventional

This trial is an open-label, single-arm clinical study. The main purpose is to verify the safety and efficacy of CAR-T cell preparations in the treatment of CEA-positive advanced malignant tumors, and to obtain the recommended dose and infusion scheme of CAR-T cell preparations for the treatment of patients with CEA-positive advanced malignant tumors.

NCT ID: NCT05396300 Recruiting - Colorectal Cancer Clinical Trials

A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors

Start date: May 25, 2022
Phase: Phase 1
Study type: Interventional

This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CEA-positive advanced malignant solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.

NCT ID: NCT05364905 Completed - Endometrial Cancer Clinical Trials

Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial Carcinoma

ENDOVIE
Start date: May 9, 2022
Phase:
Study type: Observational

This is a national observational retrospective multi-site chart review study of patients with advanced, recurrent or metastatic endometrial carcinoma.